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ABSTRACT 
 
Background. Metabolic reprogramming is a key feature of neoplastic transformation and 
mitochondria are the most important organelles in such oncogenic process. Recent evidence suggests 
that TRAP1 is a key player in tumor-related metabolic rewiring. Most studies have addressed TRAP1-
related oncogenesis by in vitro and in vivo analyses. Little is however known on the possible 
contribution of histology to such studies. 
Study aims. This study assessed the role of histology in the study of TRAP1-related metabolic 
reprogramming. Specifically, it aimed: (i) to integrate the results of in vitro and in vivo studies with 
the histological analysis of tumor samples; (ii) to verify the correspondence between primary human 
neoplasms and animal tumor models; (iv) to identify novel fields for the study of TRAP1-related 
oncogenic cascades.  
Materials and methods. This project considered the following neoplastic settings: (i) 
neurofibromatosis type 1 (NF1)-related benign and malignant nerve sheath tumors; and (ii) germinal 
center (GC)-derived lymphoproliferative disorders. For the NF1-related tumors, morphological 
analysis and phenotypic characterization (TRAP1, HIF1a and related metabolic markers) were 
performed on: (i) human samples of plexiform neurofibroma (PN) and malignant nerve sheath tumors 
(MPNST); (ii) engineered mouse models of NF1-related neoplasms; and (iii) xenografts of MPNST. 
For GC-derived lymphomas, TRAP1 expression was assessed in non-neoplastic lymphoid tissues and 
in Burkitt lymphoma (BL), diffuse large B-cell lymphoma (DLBCL) and Hodgkin lymphoma (HL) 
samples. The immunohistochemical results were integrated with the results of in silico gene 
expression studies (Oncomine database). 
Results. Histological analysis of human PNs and MPNSTs documented the expression of TRAP1, 
HIF1a and downstream metabolic markers in both benign and malignant samples. A progressive 
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increase in the positivity for such proteins was noted along the oncogenic cascade from non-
neoplastic nerves to benign (PN) and malignant (MPNST) tumors. Similar expression patterns were 
observed in the animal tumor models. In this context, histological evaluation also proved 
instrumental: (i) to confirm the correspondence between human and animal tumors; (ii) to investigate 
the metastatic potential of MPNST xenografts; (iii) to detect the effects of TRAP1 knock-down on 
tumor cell growth and metabolic reprograming; and (iv) to highlight strongly versus minimally 
activated metabolic pathways in NF1-related oncogenic cascades.  
The histological characterization of reactive lymphoid tissues highlighted TRAP1 expression in 
subsets of GC blasts (i.e. differentiating immunoblasts and re-cycling centroblasts). The joint 
expression of TRAP1 and HIF1a in GC blasts confirmed the presence and activation of the 
TRAP1/HIF1a axis in GC physiology. In silico studies of GC-derived lymphomas showed very high 
TRAP1 mRNA levels in BL and (to a lesser extent) DLBCL and HL. Immunohistochemical analysis 
of primary tumor samples confirmed the in silico results. 
Conclusions.	 Histological analysis contributes to the understanding of tumor metabolism and 
integrates the results of in vitro and in vivo biochemical studies. In particular, it confirms the relevance 
of TRAP1 activation in NF1-related peripheral nerve sheath tumors and discloses a tight 
correspondence between primary human samples and animal tumor models. Immunohistochemical 
characterization of reactive lymphoid tissues and primary lymphoma samples also identifies specific 
TRAP1 expression profiles, possibly subtending tumor-related metabolic networks.	
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1. INTRODUCTION 
 
 Cancer cell biology relies on integrated molecular circuits, derived from the reprogramming 
of normal biochemical and signaling pathways. The number and kind of such derangements subtends 
a huge variety of neoplastic phenotypes and provides an explanation to the clinical and biological 
variability of human tumors. In order to maintain their growth and survival, cancer cells must 
nonetheless obey some general rules, broadly classifiable as (i) cancer enabling conditions and (ii) 
hallmarks of cancer (1). Hallmarks of cancer are acquired functional capabilities that allow cancer 
cell survival, proliferation and/or dissemination. These functions are made possible by general 
biological characteristics (i.e. cancer enabling conditions), which distinguish cancer cells from their 
non-neoplastic counterpart (1). 
 
1.1. Cancer enabling conditions and hallmarks of cancer 
According to Hanahan and Weinberg, cancer enabling conditions include (i) the genomic 
instability of tumor cells and (ii) the inflammatory state of premalignant and frankly malignant lesions 
(1).  
Genomic instability is a key requisite for tumor cell biology. It mainly results from DNA 
changes, leading to the generation of mutant phenotypes with increased survival capacity (2). 
Genomic instability results from increased sensitivity to mutagenic agents and/or defects of the DNA-
maintenance machinery, which physiologically detects DNA damage, activates DNA repair and 
neutralizes mutagenic molecules (3).  Genomic instability may also derive from altered surveillance 
systems of cell senescence/apoptosis and from derangements of telomeric DNA. In particular, the 
progressive shortening of telomeres leads to chromosomal end-to-end fusions and to unstable 
dicentric chromosomes. This, in turn, prompts the acquisition of tumor-promoting mutations that are 
subsequently fixed by telomerase re-activation (4).  
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The presence of tumor-favoring inflammatory infiltrates is another general requisite for 
neoplastic transformation, as recently demonstrated in both solid and hematological tumors (5, 6). 
Key protagonists of such tumor-microenvironment cross-talk are specific T lymphocytes (regulatory 
T-cells) and accessory cell subsets (tumor-associated macrophages) (7). These cells dampen anti-
tumor immune responses, favoring the ensuing of an immune-suppressive milieu that enables 
neoplastic cell survival and proliferation. Neoplastic clones, in turn, produce chemokines and 
cytokines that re-shape the tumor inflammatory microenvironment and indirectly promote tumor 
growth and dissemination (8, 9).  
Besides cancer enabling conditions, tumor cells are characterized by recurrent molecular, 
biochemical and metabolic derangements that have been summed-up into eight major “hallmarks of 
cancer”. These include: (i) sustained proliferative capacity; (ii) evasion form growth suppression; (iii) 
resistance to cell death triggers; (iv) acquisition of replicative immortality; (v) promotion of 
angiogenesis; (vi) acquisition of a metastasizing phenotype; (vii) evasion of anti-tumor immune 
responses; and (viii) reprogramming of energy metabolism (1). 
The sustained proliferative capacity of tumor cells may result from either autocrine/paracrine 
stimulation (i.e. growth factors produced by the neoplastic cell themselves or by the tumor 
microenvironment), constitutive activation of growth factor-related signaling pathways (e.g. 
amplification or activating mutations of receptors and downstream mediators) and/or disruption of 
negative feedback loops (e.g. inactivating mutations of protein phosphatase or GTPase activity) (10).  
Evasion from growth-suppressing signals largely derives from inactivating mutations in tumor 
suppressors genes (e.g. Rb and p53) (11) or in proteins involved in cell-to-cell contact inhibition (e.g. 
Merlin or  LKB1) (12).  
Resistance to cell death triggers and evasion from apoptosis may results from several 
mechanisms, including: (i) the up-regulation anti-apoptotic genes (e.g. over-expression of Bcl2 and 
related proteins); (ii) the down-regulation of tumor suppressors and DNA-damage sensors (e.g. loss 
of p53); (iii) the down-modulation of apoptotic inducers (e.g. Bax and Bak); and (iv) the reduced 
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sensitivity to extrinsic ligand-inducing death pathways (13). Recent evidence also suggests an 
oncogenic role for deranged autophagy, which may operate independently of or in concert with 
apoptosis evasion (14, 15).  
The acquisition of replicative immortality is largely mediated by telomerase re-activation, 
which enables the progressive elongation of chromosomal ends and the avoidance of cell senescence 
and apoptosis (16). Recent evidence also suggests additional (telomere-unrelated) oncogenic roles for 
telomerase, including the amplification of Wnt signaling, the enhancement of cell proliferation and 
apoptosis resistance and the involvement in DNA-damage repair and RNA-dependent RNA-
polymerase function (17, 18). Of note, specific tumor histotypes (e.g. low grade gliomas or pancreatic 
neuroendocrine tumors) also rely on telomerase-independent telomere maintenance, which involve 
recurrent mutations in the chromatin modifiers ATRX and DAXX (19). 
Three further hallmarks of cancer highlight the importance of the non-tumor 
microenvironment, which indeed contributes to neoplastic growth by providing blood supply and pro-
survival/metastasizing signals. These include induction of angiogenesis, activating invasion and 
metastasis and reprogramming tumor cell metabolism. 
Tumor cells secrete a number of angiogenic mediators (e.g. VEGF, FGF) that propel the 
development of a rich network of aberrant vessels and contribute to oxygen and nutrient delivery, 
tumor cell migration and pro-tumorigenic immune cell recruitment. Angiogenesis is induced early 
during neoplastic transformation and is partially accomplished by the endothelial trans-differentiation 
of tumor cells (20) and/or by the recruitment of bone marrow-derived vascular progenitors (21).  
Neoplastic cell invasion and dissemination is sustained by both cell-intrinsic molecular 
pathways and cell-extrinsic stromal components (e.g. tumor-associated macrophages, regulatory T-
cells and mesenchymal stem cells). The latter further illustrate the importance of a tumor-permissive 
inflammatory milieu in order to acquire a fully-blown neoplastic phenotype (8, 9). 
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All of such acquired oncogenic functions require a consensus reprogramming of the metabolic 
features, enabling neoplastic cells to face challenging biochemical and environmental conditions. 
This justifies the inclusion of reprogramming energy metabolism within the hallmarks of cancer (1). 
 
1.2 Metabolic derangements in neoplastic cells 
Tumor-associated metabolic reprogramming include: (i) an increased uptake of nutrients from the 
extra-cellular compartment; (ii) the modulation of intra-cellular anabolic and catabolic pathways; (iii) 
changes in the long-range effects of cell metabolism on gene expression and micro-environmental 
shaping (22). 
Glucose and glutamine are the principal nutrients for (neoplastic and non-neoplastic) mammalian 
cells. They indeed provide carbon intermediates for several biosynthetic pathways and reducing 
power (i.e. NADH, NADPH and FADH2) to fuel ATP synthesis (22). Glutamine is also a source of 
nitrogen for the biosynthesis of nucleotides, glucosamines and non-essential amino acids and proves 
crucial for the uptake of essential amino acids from the extracellular space (22, 23). The key roles of 
glucose and glutamine prompt tumor cells to develop strategies increasing the uptake of such nutrients 
from the extracellular space. These include (i) the up-regulation of surface transporters for glucose 
(e.g. GLUT1) and glutamine (e.g. ASCT2 and SN2) (24, 25); (ii) the activation of intra-cellular 
enzymes blocking the efflux of glucose and glutamine back into the extra-cellular space (e.g. HK and 
phosphofructokinase for glucose; glutaminase for glutamine) (26, 27); (iii) the development of 
opportunistic modes for nutrient acquisition (i.e. macropinocytosis of extra-cellular molecules; 
entosis and phagocytosis of apoptotic cellular corpses) (28, 29); and (iv) the activation of self-
catabolic processes (e.g. macro-autophagy) upon long periods of nutrient deprivation (30).  
Besides nutrient uptake, tumor cells often undergo profound changes in intra-cellular metabolic 
pathways that propel biosynthetic reactions, while decreasing canonical catabolic circuits. This is 
well exemplified by the metabolic rewiring of glucose metabolism, whereby an increase in the 
glycolytic pathway is paralleled by a reduction of the tricarboxylic acid (TCA) cycle and oxidative  
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Figure 1. Biosynthetic outputs of central carbon metabolism (adapted from ref. 24).  
In cancer cells, the increased glycolytic flow leads to the accumulation of metabolic intermediates that may be used by 
several biosynthetic pathways (i.e. pentose phosphate pathway, phospholipid and amino acid biosynthesis). TCA cycle 
intermediates may also be diverted to key anabolic reactions (e.g. fatty acid, cholesterol and amino acid biosynthesis). 
________________________________________________________________________________________________ 
 
phosphorylation independently of oxygen availability (aerobic glycolysis or “Warburg effect”) (31). 
In such a context, the increased concentration of glycolytic intermediates can be diverted into 
branching pathways, generating several biosynthetic precursors (Figure 1). Glucose 6-phosphate (the 
first intermediate of glycolysis) can indeed enter the pentose phosphate pathway to generate ribose-
5-phosphate, a structural component of nucleotides (22). Fructose-6-phosphate (the second 
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intermediate of glycolysis) can be diverted to hexosamine biosynthesis, thus taking part to 
glycosylation reactions and heparan sulfate or hyaluronic acid biosynthesis (32). Dihydroxiacetone 
phosphate (a derivate of Fructose-1,6-bisphosphate) can be converted into glycerol-3-phosphate and 
participates to the synthesis of diverse phospholipids, while 3-phosphoglycerate is a non-essential 
amino acid precursor and can generate methyl donor groups and reducing power (NADPH) (22, 33). 
In a similar way, TCA intermediates can be diverted into the synthesis of fatty acids (i.e. citrate 
conversion to acetil-CoA by ATP-citrate lyase) (34) or non-essential amino acids (e.g. oxaloacetate 
conversion to asparagine and aspartate) (35). These anabolic shifts have to be counterbalanced with 
an anaplerotic influx into the TCA cycle, which is mainly sustained by glutamine (36). The latter can 
indeed be captured within mitochondria by glutaminase, and the resulting glutamate can be converted 
into the TCA intermediate a-ketoglutarate by a variety of enzymes (i.e. glutamate dehydrogenase or 
amino acid transaminases) (36). Many of such metabolic derangements are promoted by oncogenes, 
such as HIF1 (increase of glycolytic intermediates through the inhibition of pyruvate conversion to 
Acetyl-CoA) (37), Akt (induction of ATP-cytrate lyases for the biosynthesis of fatty acids) (34) and 
c-Myc (increase of glycolytic intermediates; promotion of glutamine to glutamate conversion) (25, 
38). 
Finally, the metabolic reprogramming of cancer cells can induce non-metabolic derangements 
affecting both gene expression profiles and the tumor-microenvironment interaction. Gene expression 
changes are mainly caused by metabolite-induced histone modifications (e.g. acetylation through 
acetyl-CoA; crotonylation through the tryptophan and lysine derivate crotonyl-CoA; methylation 
through the serine derivate S-adenosyl-methionine) (39-41) or by metabolite-driven regulation of 
chromatin modifier enzymes (e.g. a-ketoglutarate-dependent activation of the TET2 family of DNA 
demethylase) (22). The tumor microenvironment can instead be influenced by the accumulation of 
metabolic byproducts (e.g. lactate) or by the active modification of the extra-cellular milieu. Extra-
cellular lactate generates an immune permissive microenvironment (i.e. inhibition of dendritic cells 
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and T-cell activation; recruitment of tumor-favoring macrophage sub-populations), promotes 
angiogenesis and supports tumor invasion and metastasis (i.e. production of hyaluronic acid by 
fibroblasts; activation of matrix-degrading metalloproteinases) (42-44). Some tumors also actively 
modify the extra-cellular space to promote immune escape. This is the case of tryptophan degradation 
by tumor-derived dioxygenases (IDO1 or TDO2), which triggers amino acid deprivation-associated 
apoptosis of effector T-cells. A byproduct of such reactions (kynurenine) also promotes the 
recruitment of tumor-supporting regulatory T-cells (45). 
Taken together, these data highlight the key role of metabolic reprogramming in tumor cell growth 
and survival. Despite most of such derangements are mediated by well-known oncogenes and 
transcription factors, recent studies have pinpointed the existence of novel (and only partially 
characterized) metabolic regulators. One of such proteins is the chaperone TRAP1. 
 
1.3 The role of TRAP1 in tumor cell biology 
TRAP1 is a 75kDa chaperone, belonging to the HSP90 family of proteins. Several lines of 
evidence suggest a key role for TRAP1 in the metabolic reprogramming of tumor cells (46). These 
functions are largely mediated by unique structural and functional features, which make TRAP1 a 
master regulator of mitochondrial respiration and HIF1-mediated transcriptional programs. 
 
1.3.1 TRAP1 structure and physiological functions 
TRAP1 is an ATP-binding homodimeric protein, characterized by 60% homology with HSP90. 
Its protomers consist of three major domains: the N-terminal domain (responsible for ATP binding 
and hydrolysis), the C-terminal domain (providing a dimerization site), and the middle domain 
(completing the ATP-binding pocket and hosting the client recognition surface). Notably, TRAP1 is 
the only HSP90-family member containing a N-terminal mitochondrial import sequence, which leads 
to its selective localization to the mitochondrial matrix (47).  
TRAP1 function relies on a well-characterized cycle of structural states, leading to ATP 
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hydrolysis and to client protein remodeling. In detail, three conformational states have been 
described, including: (i) an open conformation (i.e. the apo state); (ii) a closed conformation, with a 
N-terminal extension between the protomers; and (iii) an intermediate conformation, with the N-
terminal domains in close proximity (48). Upon binding of two ATP molecules, TRAP1 adopts a 
closed asymmetric conformation. This induces the first ATP hydrolysis, with subsequent structural 
changes and client remodeling. The second ATP hydrolysis confers a compact conformation to the 
protein, which induces the release of both the client and the two ADP molecules (49-51). 
Several lines of evidence suggest pleiotropic functions for TRAP1, which are at least partially 
context- and cell-dependent. Many studies have indeed demonstrated a role for TRAP1 in the 
regulation of intra-cellular ROS levels and in cellular responses to oxidative stress (52, 53). In 
particular, TRAP1 may inhibit apoptosis by antagonizing the opening of the mitochondrial 
permeability transition pore (PTP). This effect can be mediated by the direct inhibition of cyclophilin 
D (a PTP-inducer) (54, 55) or by a reduction of ROS production from the complex II of the respiratory 
chain (also known as succinate dehydrogenase) (56). In a different biological context (i.e. 
regenerating liver after hepatectomy), TRAP1 has been associated with promotion of hepatic growth, 
modulation of intra-hepatic inflammation and tuning of fatty acid metabolism (57). Many of such 
functions are likely related to TRAP1 pivotal regulation of mitochondrial metabolism. 
TRAP1 levels and functions are regulated at both a transcriptional and post-translational level. 
The latter mechanism mainly includes the phosphorylation of specific residues, which either increases 
its anti-oxidant functions (e.g. PINK1-mediated Ser/Thr phosphorylation) or finely tunes its 
regulation of the respiratory chain (e.g. c-Src and ERK1/2-mediated phosphorylation) (46, 58, 59). 
While the oncogenic relevance of PINK1-mediated TRAP1 regulation is largely unknown, recent 
evidence suggests a key role for ERK1/2-mediated TRAP1 activation in the metabolic 
reprogramming of tumor cells (46). This justifies the observation of high TRAP1 expression levels 
in several tumor histotypes (57, 60) and the positive correlation between TRAP1 levels, tumor 
progression and metastatic potential (27, 61-63).  
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1.3.2  TRAP1 as a key player in tumor cell metabolism  
TRAP1 plays a key role in the metabolic reprogramming of tumor cells by contributing to the 
acquisition of an aerobic glycolytic phenotype (i.e. increased glycolytic activity with decreased TCA 
cycle and OXPHOS reactions) (57). This is largely mediated by its interaction with the complex II 
and complex IV of the respiratory chain. In detail, TRAP1 down-regulation of complex IV (i.e. 
cytochrome oxidase) inhibits mitochondrial respiration and promotes the accumulation of acetyl-CoA 
and TCA cycle intermediates, which can be used in key anabolic pathways (i.e. synthesis of free fatty 
acids and/or non-essential amino acids) (59, 64, 65). TRAP1 inhibition of complex II (i.e. succinate 
dehydrogenase) instead leads to an increase of intra-cellular succinate levels, with subsequent 
inhibition of prolyl-hydroxylase (PHD) and stabilization of HIF1a (a PHD target) (64). This promotes 
the over-expression of genes involved in glucose metabolism (e.g. hexokinase 2 [HK2], pyruvate 
kinase M2 [PKM2], glucose transporters [GLUT1, GLUT3]), cell growth (e.g. Cyclin F2, TGFa, 
TGF-b), neo-angiogenesis (e.g. VEFG and its receptor) and stromal invasion (e.g. metalloproteinase 
2, c-MET, fibronectin 1) (66). These metabolic derangements, together with its anti-apoptotic (54, 
56) and proteostatic functions (67), make TRAP1 a key player in human oncogenic cascades. 
 
1.4 Paradigms of human hematological and non-hematological tumors 
The study of tumor metabolism is potentially hampered by the biological heterogeneity of 
human neoplasms (1). Similar mediators and signaling cascades can indeed exert opposite roles in 
different biological and micro-environmental contexts (68). The study of tumor metabolism thus 
requires the identification of representative models to be assumed as paradigms of human cancer. For 
their well-characterized pathobiological mechanisms and non-neoplastic counterparts, 
neurofibromatosis type 1 (NF1)-related peripheral nerve sheath tumors and germinal center (GC)-
derived peripheral B-cell lymphomas are good examples of such models.  
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1.4.1 Neurofibromatosis Type 1 (NF1) and NF1-associated peripheral nerve sheath tumors 
Neurofibromatosis type 1 is a genetic syndrome, first described by Friederich von 
Rechlinghausen in 1882. It is one of the most common familial tumor predisposition syndrome 
with an estimated incidence of 1 in 3000 newborns. NF1 is an autosomal dominant disease with 
high penetrance, caused by mutations of the Nf1 gene on chromosome 17q11.2. Almost half of 
cases occur de novo (i.e. NF1 with no familial history), as a result of newly acquired Nf1 
mutations during parental oogenesis or spermatogenesis.  
The Nf1 gene encodes neurofibromin, a 220-to-250 KDa GTPase-activating protein that 
negatively regulates the MAPK pathway by promoting Ras-bound GTP hydrolysis. As such, 
inactivating Nf1 mutations lead to the constitutive activation of the MPAK pathway and promote 
uncontrolled cell proliferation and tumor development (69).  
The clinical features of NF1 are greatly variable and consensus criteria have been established to 
improve the disease diagnosis (70). The prototypic clinical manifestations of NF1 include: (i) 
multiple cutaneous and soft tissue neurofibromas; (ii) café-au-lait cutaneous macules and 
axillary/groin freckles; (iii) iris hamartomas (also known as Lisch nodules); (iv) a higher risk of 
central nervous system neoplasm (optic pathway pylocytic astrocytoma; diffuse grade II to grade 
IV gliomas); and (v) dysplastic lesions of the sphenoid bone and long bone cortex. NF1 patients 
are also at increased risk of developing malignant peripheral nerve sheath tumors (MPNSTs) 
(71). Of note, the clinical presentation is highly variable and depends on the disease expressivity. 
A genotype-phenotype correlation is lacking, but whole gene deletions lead to a severe phenotype 
(also known as “Nf1 microdeletion syndrome”) with mental retardation, facial dysmorphism, 
numerous neurofibromas and higher risk of MPNST development (72, 73), whereas in the 
majority of cases point mutations, as well as  mosaic or segmental forms, disclose more limited 
and indolent disease presentations. 
The most common and clinically relevant NF1-related neoplasms are peripheral nerve sheath 
tumors (71). These include both benign (i.e. neurofibromas) and highly malignant (i.e. MPNST) 
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entities. Histologically, neurofibromas are sub-classified into: (i) localized cutaneous 
neurofibroma (CN); (ii) plexiform neurofibroma (PN); and (iii) diffuse neurofibroma (DN). 
While CNs frequently affect also non-NF1 patients, PN and DN are virtually exclusive of NF1. 
Irrespective of the specific histotype, neurofibromas consist of an ill-defined proliferation of 
benign-looking Schwann cells, with scant cytoplasm and wavy nuclei. Neoplastic cells disclose 
a fascicular to disarranged growth pattern and are embedded in a rich non-neoplastic 
microenvironment, consisting of mast cells, fibroblasts/myofibroblasts and scattered 
lymphocytes and histiocytes. The extra-cellular stroma is often myxoid and contains numerous 
shredded carrot-like bundles of collagen. CNs are nodular, poorly circumscribed dermal lesions, 
frequently entrapping skin adnexa and nerve fibers. DNs are plaque-like dermal-hypodermal 
tumors, diffusely infiltrating the connective tissue and frequently displaying rounded aggregated 
of fibrillary material, reminiscent of tactile bodies (“Meissner-like corpuscles”) (74). CNs and 
DNs have minimal (if any) potential of malignant transformation (75).  
PNs are NF1-defining peripheral nerve sheath tumors, typically arising in the limbs, trunk and 
paraspinal region. They consist of multiple, variably oriented nerve fascicles that are expanded 
by a disorganized proliferation of Schwann cells with loose stroma. The connective tissue 
between the abnormal nerves is frequently occupied by a neurofibromatous proliferation closely 
resembling DNs. Unlike CN and DN, PN can undergo malignant transformation to MPNST (74). 
The molecular genetics of neurofibroma has mostly been studied in the setting of NF1. In these 
cases, the neoplastic transformation of Schwann cells is likely the results of the bi-allelic 
inactivation of the Nf1 gene (i.e. germline mutation in one allele, followed by a somatically-
acquired mutation in the second allele) (76). Anecdotal evidence supports the notion that sporadic 
neurofibromas have similar pathogenesis (i.e. somatic inactivation of both Nf1 alleles) (77). 
MPNSTs are aggressive soft tissue tumors disclosing neuro-ectodermal differentiation, 
putatively originating from the neoplastic transformation of peripheral nerve sheath-constituting 
cells. MPNSTs typically arise in the proximal limbs and paraspinal regions. In many cases, a 
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direct connection/close contiguity with major nerves (e.g. the sciatic nerve) and/or nerve roots is 
documented. MPNSTs occur either sporadically or in NF1 patients. In the latter case, the lifetime 
risk of developing MPNST is estimated between 2% and 10% (78). MPNSTs present as large, 
often necrotic and hemorrhagic masses. Low grade lesions may however simulate PNs or less 
aggressive sarcoma types. Histologically, MPNSTs are characterized by a variety of cytology 
and growth patterns that often mask their peripheral nerve sheath derivation. The tumor is indeed 
composed by spindle to epithelioid and/or pleomorphic malignant cells, occasionally featuring 
heterologous differentiation toward chondrosarcomatous, osteosarcomatous and/or 
rhabdomyosarcomatous components. Tumor cells usually disclose a fascicular to storiform 
growth pattern. A rather typical finding is the alternation of hyper- and hypo-cellular areas, with 
dense cell aggregates around medium-sized blood vessels. Fibrosarcoma-like herringbone areas 
and branching hemangiopericytoma-like vessels can also be documented. Given the broad 
variety of morphological features, a definite diagnosis of MPNST is only made by the presence 
of a clear-cut peripheral nerve sheath phenotype (e.g at least focal immunohistochemical 
positivity for S100 and/or SOX10).  
The molecular genetics of MPNSTs have been extensively studied. Most cases disclose a 
complex karyotype with structural and numerical chromosomal derangements. Recurrent 
monosomy of chromosome 22 and amplification of distal chromosome 17q have been 
documented in small subsets of cases (71). At a gene level, Nf1 inactivation is frequently 
documented in both NF1-related and sporadic cases, likely representing an early oncogenic 
event. Recurrent imbalances also include p16 inactivation and PRC2 loss of function. The latter 
is a polycomb repressor complex that regulate the transcription of several Ras-dependent genes 
(79). In the MPNST setting, its deregulation amplifies the abnormal MAPK-related signals, 
deriving from Nf1 inactivation (80). At present, nothing is known about the functional effects of 
such molecular derangements on tumor cell metabolism. Furthermore, no data are as yet available 
on the metabolic rewiring occurring along the PN to MPNST oncogenic cascade. 
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1.4.2 Germinal center-derived B-cell lymphoproliferative disorders 
Peripheral B-cells lymphomas are a broad group of lymphoproliferative disorders, derived from 
the neoplastic transformation of mature B lymphocytes. The current classification of such tumors 
is based on their putative non-neoplastic counterpart and include entities derived from: (i) pre-
germinal center (GC) B-cells (i.e. lymphocytes that are not antigen-primed and have not 
undergone GC reactions); (ii) GC B-cells (i.e. lymphocytes passing through the GC and up-
regulating GC-related genes); and (iii) post-GC B-cells (i.e. lymphocytes that have passed 
through the GC and are committed to plasma cells or memory B cell differentiation) (81).  
The majority of peripheral B-cell lymphomas derive from GC B-cells, given the complex 
chromosomal and genetic events that physiologically occur within this anatomic compartment. 
The GC is indeed the site of immunoglobulin gene somatic hyper-mutation (SHM) and class 
switch recombination (CSR) (82). These biological processes result from a sharp functional and 
anatomic compartmentalization, by which different lymphoid populations segregate into distinct 
GC areas. The GC consists of a dark zone (DZ) and a light zone (LZ). The former is populated 
by large proliferating centroblasts, with coarse chromatin and multiple peripherally-located 
nucleoli. The latter is populated by mature centrocytes with irregular nuclear contours and dense 
chromatin. In the DZ, antigen-primed B-cells over-express the transcriptional regulator BCL6 
and undergo SHM. In the LZ, the centroblasts acquire a centrocyte morphology, up-regulate 
IRF4 and BLIMP1 and undergo CSR. They can then re-enter the DZ (for a further cycle of SHM) 
or leave the GC to terminally differentiate into plasma cells or memory B-cells (83). The 
molecular bases of LZ fate decision are only partially elucidated, but recent evidence suggests a 
key role for MYC and IRF4/BLIMP1 transcription factors (82). MYC expression would promote 
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Figure 2. Molecular bases of LZ B-cell fate decision (adapted from ref. 85). 
Antigen-primed LZ B-cells can either differentiate into plasma cells or re-enter the DZ for a further cycle of somatic 
hypermutation (SHM). Plasma cell differentiation is promoted by transcription factors such asIRF4 and BLIMP1, 
while DZ re-entry is prompted by c-Myc and REL expression. 
____________________________________________________________________________________________ 
 
 
the re-entry of B-cells into the DZ (84), while IRF4 and BLIP1 inhibit BCL6 transcription and 
prompt the terminal differentiation of B-cells (83, 85) (Figure 2). 
This complex immunologic scenario provides a framework to the biology and clinic-pathological 
features of GC-derived peripheral B-cell lymphomas, which include: (i) follicular lymphoma 
(FL); (ii) Burkitt lymphoma (BL); (iii) a subset of diffuse large B cell lymphomas, not otherwise 
specified (DLBCL); and (iv) Hodgkin lymphomas (HL).  
FL represents about 20% of non-Hodgkin lymphomas and affects adult to elderly patients with a 
clear-cut female preponderance (86). Histologically, the tumor consists of a heterogeneous 
population of neoplastic cells with variable proportions of mature centrocytes and proliferating 
centroblasts. The cells are arranged in a nodular, nodular and diffuse, or purely diffuse growth 
pattern (81). Based on the centroblast content, FL is graded into a three-tiered scale (G1: <5 
centroblasts/10 high-power fields [HPF]; G2: 5-15 centroblasts/10 HPF; G3: >15 centroblasts/10 
HPF, further sub-classified into G3A and G3B, depending on the presence or absence of residual 
centrocytes). The majority of cases are either G1, G2 or G3A lymphomas and disclose a relatively 
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indolent clinical course (87). By contrast, G3B FLs are biologically aggressive tumors, which 
clinically resemble DLBCL (86). Gene expression studies have highlighted a LZ origin for FLs, 
irrespective of the tumor grade (88). 
DLBCL and BL are clinically aggressive lymphomas, composed by sheets of blasts with no 
evidence of mature centrocytes. DLBCLs are a heterogeneous group of tumors, accounting for 
about 40% of all non-Hodgkin B-cell lymphoma. They can arise de novo or as secondary 
transformation of prior low-grade neoplasms. DLBCLs are composed of large blasts with either 
centroblastic, immunoblastic or anaplastic morphology (81). The tumor phenotypic and 
molecular features are highly variable and correlate with the putative cell of origin (89). A subset 
of DLBCLs indeed discloses gene expression profiles and immunohistochemical features akin to 
GC-residing B-cells (i.e. GCB type DLBCL), while others have molecular and phenotypic 
features closer to B-cells committed to post-GC differentiation (i.e. ABC type DLBCL). A third 
group has poorly-defined molecular features and (for clinical and diagnostic purposes) is lumped 
together with the ABC type into a “non-GCB type” category (89, 90). Beyond the cell of origin 
stratification, recent studies have highlighted further DLBCL-specific transcriptional programs 
and more complex molecular landscapes (91-94). Little is however known on the metabolic 
features of these lymphomas. 
BL is much rarer than DLBCL, accounting for only 1-2% of non-Hodgkin lymphomas. It 
frequently affects children and young adults and constitutes up to 50% of pediatric lymphoma 
cases. Three clinical variants are recognized: (i) endemic (i.e. African) BL; (ii) sporadic BL (most 
frequently encountered in Western countries); and (iii) immunodeficiency-related (commonly 
HIV-associated) BL. Histologically, the tumor is composed by medium-sized, immature-looking 
cells with finely-dispersed chromatin and inconspicuous nucleoli. Scattered histiocytes are 
frequently present within the neoplastic proliferation and confer a “starry sky” pattern to the 
tumor. The neoplastic cells invariably express GC-specific markers (Bcl6 and CD10) and are 
consistently negative (or only weakly positive) for Bcl2. BL is a highly proliferative tumor, with 
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a mean Ki67 index >98% (81). Cytogenetically, the tumor cells invariably disclose translocations 
that juxtapose the MYC gene on chromosome 8q24 to the immunoglobulin genes on 
chromosomes 14q11, 2p12 or 22q11 (95). This, in turn, leads to the oncogene constitutive over-
expression and to the uncontrolled proliferation of tumor cells. Endemic and immunodeficiency-
related BLs are frequently associated with EBV infection, while sporadic cases rarely feature 
such an association (96). Unlike FL and DLBCL, gene expression studies indicate a DZ origin 
for BL (88). 
HLs account for about 15% of all lymphoproliferative disorders and disclose peculiar clinic-
pathological and biological features. They frequently arise in adolescents and young adults, 
present as cervical and/or mediastinal lymphadenopathies and are histologically characterized by 
small numbers of neoplastic cells, embedded in a rich inflammatory microenvironment. Tumor 
cells are large, with mono/multi-lobated nuclei and abundant slightly eosinophilic cytoplasm 
(81). Based on histological and clinical features, HLs are classified in two entities: (i) classical 
HL (cHL) and (ii) nodular lymphocyte-predominant HL (NLPHL). cHL is characterized by both 
mononuclear (Hodgkin) and multinucleated (Reed-Sternberg) neoplastic cells. Hodgkin and 
Reed-Sternberg (HRS) cells are closely related to each other and disclose a B-cell defective 
phenotype, with strong positivity for CD30 (100% of cases) and CD15 (85% of cases), weak 
positivity for PAX5 and almost complete negativity for CD20, CD22, CD79a and CD19. 
According to the micro-environmental features, four variants of cHL are described (i.e. nodular 
sclerosis, mixed cellularity, lymphocyte-rich and lymphocyte-depleted variants) (97). NLPHL is 
characterized by slightly different neoplastic cells, referred to as LP elements. These are large 
blast-like cells with abundant cytoplasm, convoluted nuclei and multiple, small basophilic 
nucleoli. Unlike RSH, they have a full B-cell phenotype (strong positivity for PAX5, CD20, 
CD22, CD79a and CD19), rarely express CD30 and are invariably negative for CD15 (98). The 
majority of NLPHL disclose a nodular growth pattern, with LP cells residing within expanded 
and distorted GCs. Rare immuno-architectural variants are also described (i.e. serpiginous; 
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nodular with prominent extra-nodular LP cells; T-cell rich nodular; T-cell/histyocyte-rich large 
B-cell lymphoma-like; and diffuse B-cell rich pattern) (99). The molecular features and 
biological origin of HRS and LP cells have long been debated. Recent gene expression analysis 
on micro-dissected neoplastic cells have however demonstrated a GC origin for both cHL and 
NLPHL. In detail, LP cells may originate from GC lymphocytes of the LZ that are undergoing 
differentiation into memory B-cells (100). By contrast, cHL likely derive from LZ B-cells that 
have undergone abortive plasma cell differentiation (101, 102). Similarly to what reported for 
non-Hodgkin lymphomas, little is currently known on the metabolic features of both cHL and 
NLPHL. 
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2. STUDY AIMS 
 
This study assessed the role of histology in the study of tumor cell metabolism. In particular, it 
aimed: 
- To apply morphological, morphometric and immunohistochemical analysis to the study 
of TRAP1-related oncogenic cascades; 
- To integrate the results of in vitro and in vivo studies with the histological assessment 
of tumor samples; 
- To verify the correspondence between human neoplasms and tumor animal models; 
- To identify novel fields for the study of TRAP1-related oncogenic cascades.  
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3. MATERIALS AND METHODS 
 
3.1 Histological samples 
 The histological characterization of TRAP1-related oncogenic cascades was organized in two 
sections: (i) a non-hematological tumor branch (NF1-related peripheral nerve sheath tumors); and (ii) 
a hematological tumor branch (GC-derived peripheral B-cells lymphomas and Hodgkin lymphomas). 
As for the non-hematological tumor branch, both primary human neoplasms and tumor animal 
models were analyzed. In detail, the primary human samples included: (i) 10 cases of sub-
cutaneous/soft-tissue PN; (ii) 10 cases of MPNST from NF1-patients; and (iii) 5 surgical samples of 
major nerve trunks (non-neoplastic counterpart of both PN and MPNST). All cases were retrieved 
from the archives of the General Pathology and Surgical Pathology Unit, Department of Medicine-
DIMED (University of Padova – Italy). The animal tumor models included: (i) 7 paired (TRAP1 
wild-type and knock-down) PN samples from an engineered mouse model (see below); (ii) 5 paired 
(TRAP1 wild-type and knock-down) MPNST from an engineered mouse model (see below); (iii) 5 
patient-derived tumor xenografts (PDTX) of MPNST (kindly provided by Dr Conxi Lazaro, 
Translational Research Laboratory ICO-IDIBELL, L'Hospitalet de Llobregat; Barcelona – Spain) 
(103); (iv) 5 tumor xenografts obtained from the sub-cutaneous injection of nude mice with 
immortalized cisMPNST cells (i.e. murine MPNST cells lacking both Nf1 and TP53 genes, kindly 
provided by Dr Le and co-workers, University of Texas Southwestern Medical Center, Dallas - TX, 
USA). 
  The hematological tumor branch considered primary lymphoma samples from patients with 
DLBCL (n=33), BL (n=5), cHL (n=5), and NLPHL (n=5). DLBCLs included both adult and pediatric 
cases, with either a GCB (n=28) or non-GCB (n=5) phenotype, according to Hans algorithm (90). 
Lymph node (n=5) and tonsil (n=5) samples with reactive lymphoid hyperplasia were also included 
(non-neoplastic counterpart of the aforementioned lymphoma entities). All adult cases were retrieved 
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from the archives of the General Pathology and Surgical Pathology Unit, Department of Medicine-
DIMED (University of Padova – Italy). Pediatric cases were instead obtained from the national 
archive of the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP; Surgical Pathology 
Unit, San Bortolo Hospital; Vicenza – Italy). For all samples, the institutional regulations on research 
on human and animal tissues were followed, according to the Declaration of Helsinki. 
 
3.2 Engineered mouse model of NF1-related PN and MPNST 
Mouse models of NF1-related PN and MPNST were obtained through a collaboration with 
Prof. Lu Le, University of Texas Southwestern Medical Center (Dallas - TX, USA). In summary, 
murine nerve sheath tumors were obtained by isolating dorsal root ganglia (DRG) from E13.5 
engineered mouse embryos (i.e. embryos carrying loxP sequences adjacent to specific target genes). 
The obtained cells were subsequently infected with adenovirus carrying the Cre recombinase. Floxed 
and control cells were implanted in the sciatic nerve of nude mice to develop discrete tumor masses 
(104). The murine model of NF1-related PN was obtained by using embryonal DRG cells carrying 
Nf1flox/flox genes (i.e. tumor precursors with inducible loss of the sole Nf1 gene). Murine NF1-related 
MPNSTs were instead obtained by using donor embryos with both Nf1flox/flox and TP53flox/flox genes 
(i.e. tumor precursors with inducible loss of both Nf1 and TP53).  
To assess TRAP1 oncogenic role in NP and MPNST murine models, expression of the protein 
was modulated through RNA interference, as previously described (i.e. adenovirus-mediated 
transfection of either TRAP1-targeting shRNAs or scrambled shRNAs via pLKO.1 plasmids) (64). 
 
3.3 Tissue microarray (TMA) generation 
 Tissue microarrays (TMA) were obtained from primary human lymphoma samples with 
sufficient diagnostic material, as previously reported (105). This allowed the cost-effective 
assessment of a large number of cases under standardized and reproducible conditions. In detail, after 
selection of representative tumor areas, 2 tissue cores were obtained for each donor block (core 
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diameter: 0.1 cm). Tissue cores were then included in a recipient block together with positive and 
negative controls (positive controls: reactive lymph nodes and tonsils; negative controls: hepatic and 
cardiac tissue). From each TMA block, 4 µm-thick tissue sections were obtained for 
immunohistochemical analysis. The TMA construction was performed by using the Galileo TMA 
CK3500 device (Integrated System Engineering, Milan – Italy). 
 
3.4 Morphological characterization 
Each tumor sample was morphologically characterized: (i) to confirm the originally proposed 
diagnosis (primary human samples); (ii) to assess the correspondence between human neoplasms and 
tumor animal models (engineered mice and xenograft models); and (iii) to select the most 
representative tumor areas for immunohistochemical analysis. 
 Morphological evaluation was performed on 3 to 4 µm-thick tissue sections stained with 
standard hematoxylin and eosin (H&E). As for the solid tumor branch of the study, histological 
criteria for the diagnosis of PN were set as follows: (i) presence of disarranged nerve bundles with 
loose to myxoid stroma; (ii) detection of variable stromal and inflammatory cell types (i.e. neoplastic 
Schwann cells, fibroblasts/myofibroblasts, mast cells, lymphocytes, plasma cells and histiocytes); 
(iii) lack of atypical cytological features; (iv) absent or extremely low mitotic activity (<1 mitosis/10 
high-power fields); and (v) lack of tumor cell necrosis (74). By contrast, histological criteria for the 
diagnosis of MPNST included: (i) a highly cellular proliferation of atypical mesenchymal cells, 
arising from (or lying in close proximity to) major nerve trunks; (ii) the paucity of non-neoplastic 
inflammatory and/or stromal cells; (iii) the documentation of obvious mitotic activity (>5 mitoses/10 
high-power fields); and/or (v) the documentation of tumor cell necrosis (74). As for the hematological 
tumor branch, each entity was diagnosed according to the revised 4th edition of the WHO 
Classification of lymphoid tumors (81). 
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3.5 Immunohistochemical analysis  
Immunohistochemical analysis was performed on 3 to 4 µm-thick tissue sections, stained with the 
following primary antibodies: anti-TRAP1 (clone sc-73604, Santa Cruz, Dallas – TX, USA), anti-
HIF1a (clone NB100-449, Novus Biologicals, Littleton – CO, USA), anti-PKM2 (clone D78A4, Cell 
Signaling Technology, Danvers – MA, USA), anti-Nf1 (clone sc-20017, Santa Cruz, Dallas – TX, 
USA9), anti-GLUT1 (clone, Dako), anti-HK2 (clone sc-6521, Santa Cruz, Dallas – TX, USA), anti-
Glutamine Synthetase (clone ab16802, Abcam, Cambridge - UK), anti-CD117 (polyclonal, Dako, 
Glostrup - Denmark), anti-PAX5 (clone 1H9; Thermo Fisher Scientific, Waltham – MA, USA), anti-
cMyc (clone EP121, Epitomics, Burlingame, CA – USA), and anti-IRF4/MUM1 (clone MUM1p, 
Dako, Glostrup - Denmark). Antigen retrieval was performed with heat/EDTA in the Bond-Max 
automated immunostainer (Leica Biosystems, Milan – Italy), as previously described (105).  
Immunohistochemical analysis was performed with both single (TRAP1, HIF, Nf1, GLUT1, 
PKM2) and double immunostaining (TRAP1/CD117, TRAP1/PAX5, TRAP1/c-Myc, TRAP1/ 
IRF4). For single immunostaining the BondTM Polymer Refine Detection kit (Leica Biosystem, 
Newcastle, UK) was used. Double immunostaining were performed using the BondTM Polymer 
Refine Detection and BondTM Polymer Refine Red Detection kits (Leica Biosystem). Histological 
pictures were acquired by the DFC420 digital camera and software (Leica Biosystems). 
 
3.6 In silico gene expression analysis 
To assess TRAP1 mRNA expression levels in non-Hodgkin B-cell lymphomas and Hodgkin 
lymphoma, the Oncomine database and gene microarray analysis tool was explored (August 2018; 
http//:www.oncomine.org) (106). Inclusion criteria for the in silico analysis were set as follows: (i) 
gene expression studies had to assess TRAP1 mRNA levels in both BL, DLBCL, and HL (of any 
type); (ii) TRAP1 expression data had to be assessed in ≥ 5 cases for each considered entity. Such 
inclusion criteria were met by three publicly available data sets (100, 107, 108). 
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3.7 Morphometric and statistical analysis 
Morphometric analyses were performed through digital imaging techniques, by using the DMD108 
microscope and software (Leica Microsystems, Milan - Italy). Statistical analysis was performed 
using non-parametric tests to compare quantitative variables (Mann-Whitney U test). Differences 
between groups were considered statistically significant for p-values below 0.05. 
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4. RESULTS 
 
4.1 TRAP1 in NF1-related peripheral nerve sheath tumors 
 The histological characterization of NF1-related peripheral nerve sheath tumors was first 
conducted on primary human neoplasms. The obtained results were then compared with the 
morphological and immunohistochemical features of the animal tumor models.  
 
 4.1.1 Histological characterization of human PNs and MPNSTs 
 The morphological and immunohistochemical characterization of primary human samples 
was performed by comparing PNs and MPNSTs with their non-neoplastic counterpart (i.e. peripheral 
nerve trunks). In such samples, the whole TRAP1-related oncogenic cascade was 
immunohistochemically tested, moving from the assumption that Nf1 loss would prompt MAPK 
hyper-activation, TRAP1-mediated stabilization of HIF1a and increased transcription of HIF1-target 
genes. In line with this hypothesis, both PN and MPNST disclosed consistent immunohistochemical 
negativity for Nf1, with strong expression of pERK and variable positivity for TRAP1, HIF1a and 
HIF1 targets (i.e. GLUT1, HK2, PKM2). Non-neoplastic nerve trunks were instead negative for both 
TRAP1 and its downstream targets (Figure 3A). 
In detail, TRAP1 was expressed by only a subset of cells within PNs, while strong positivity 
was observed in all MPNSTs. In all cases, TRAP1 expression disclosed a finely granular cytoplasmic 
pattern, consistent with mitochondrial localization. Furthermore, double immunostain for TRAP1 and 
CD117 disclosed two subsets of TRAP1-expressing cells: (i) a TRAP1-positive/CD117-positive 
population, consistent with intra-tumor (non-neoplastic) mast cells; and (ii) a TRAP1-
positive/CD117-negative population, with cytological and topographic features consistent with 
neoplastic Schwann cells. Similar expression patterns were observed for HIF1a, with complete 
negativity of non-neoplastic nerves, weak-to-moderate positivity in subsets of NP cells and diffuse 
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positivity in all MPNSTs. Of note, HIF1a downstream targets disclosed variable expression profiles. 
In particular, PNs featured partial positivity for PKM2 with nearly complete negativity for GLUT1 
and HK2. By contrast, MPNSTs were characterized by higher (yet variable) GLUT1 and HK2 
positivity, with strong and diffuse expression of PKM2 in most cases. Taken together, these results 
suggest a progressive up-regulation of the TRAP1/HIF1a axis along the MPNST oncogenic cascade 
(Figure 3A).  
Notably, the over-expression of genes related to glucose metabolism (i.e. GLUT1, HK2 and 
PKM2) was paralleled by the up-regulation of Glutamine Synthetase (GLUL), a key enzyme for 
glutamine biosynthesis and metabolism. Indeed, GLUL was almost completely absent in non-
neoplastic peripheral nerves, partially positive in PNs and strongly expressed in all MPNSTs (Figure 
3A). 
 
4.1.2 Histological characterization of animal tumor models 
The histological characterization of animal tumor models was mainly aimed to: (i) evaluate 
the correspondence between primary human neoplasms and in vivo murine tumors; (ii) define the 
expression and distribution of TRAP1 and its downstream targets; (iii) assess the histological effects 
of TRAP1 knock-down in both PN and MPNST; and (iv) define the metastatic potential of sub-
cutaneous MPNST xenografts. 
As for the in vivo engineered mouse model, the morphological analysis of sciatic nerve tumors 
disclosed a perfect correspondence between human neoplasms and their putative murine counterpart. 
In particular, sciatic tumors arose from Nf1floxed/floxed DRG cells recapitulated the histological features 
of PN (i.e. haphazardly arranged nerve bundles with loose stroma, benign-looking Schwann cells and 
varying numbers of stromal and inflammatory cells). By contrast, Nf1floxed/floxed;TP53 floxed/floxed cells 
gave rise to biologically aggressive neoplasms akin to MPNSTs (i.e. large necrotic masses composed 
of atypical, mitotically active neoplastic cells with little
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Figure 3. Histological features of NF1-related peripheral nerve sheath tumors.  
A. In human samples, TRAP1, its downstream targets (GLUT1, HK2 and PKM2) and GLUL were negative in normal 
nerves, weakly/partially positive in PNs and highly expressed in MPNSTs. B. In an engineered mouse model, shTRAP1 
PNs were significantly smaller than wild-type tumors (main diameter assessed in millimeters by digital imaging 
techniques); no significant differences in tumor diameter were instead noted between shTRAP1 and wild-type MPNSTs. 
In MPNST, TRAP1 silencing was nonetheless associated with the down-modulation of HIF1a, HIF1 targets and GLUL 
(H&E and peroxidase stains; original magnification 20x. The asterisk indicates a p-value <0.05). 
Plexiform	neurofibromas 
MPNST 
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intervening stroma). This murine models also allowed to evaluate the histological effects of TRAP1 
silencing in NP and MPNST. In particular, TRAP1 knocked down Nf1floxed/floxed cells generated much 
smaller tumors compared to wild-type cells (mean tumor size, as histologically assessed: 0.19 cm 
versus 0.42 cm; p< 0.05) (Figure 3B). No statistically significant differences in tumor size were 
instead noted between MPNSTs with knocked-down or wild-type TRAP1 (mean tumor size: 0.70 cm 
versus 0.65 cm; p= 0.27). In such tumors, however, TRAP1 silencing was associated with decreased 
expression of HIF1a, HIF1-regulated genes (i.e. PKM2, HK2 and GLUT1) and GLUL (Figure 3B). 
 Immunohistochemical analysis was thoroughly applied to assess TRAP1 expression in normal 
murine tissues and to characterize TRAP1, HIF1a, HIF1 targets and GLUL expression along the 
MPNST oncogenic cascade. In non-neoplastic tissues of wild-type mice, TRAP1 expression was 
documented in cardiomyocytes, brown adipocytes, peri-venular hepatocytes, renal tubules and 
histiocytes of the splenic red pulp, with consistent negativity in peripheral nerves, skeletal muscles, 
blood vessels, pneumocytes, lymphocytes of the splenic red pulp and primary lymphoid follicles, 
colocytes and renal glomerular cells (Figure 4A-H).  The immunohistochemical profile of murine PN 
and MPNST tumors recapitulated the one observed in human samples (i.e. progressive increase of 
TRAP1 and HIF1a expression from non-neoplastic nerves to PN and MPNST; variable positivity for 
HIF1 targets, with highest expression of PKM2; progressive increase in GLUL positivity). 
The immunohistochemical characterization of PDTXs was in keeping with what observed in 
primary human samples and in vivo engineered MPNSTs. By contrast, xenografts of the immortalized 
cysMPNST cell line were characterized by slightly different expression profiles (weaker HIF1a, HK2 
and GLUL compared to primary human samples). This latter model proved instrumental also to 
characterize the metastatic potential (and overall biological aggressiveness) of sub-cutaneous tumor 
xenografts. In particular, autopsy and histological examination at the end of the experiment (18 days 
after sub-cutaneous injection of 106 cysMPNST cells) did not show any evidence of disseminated 
disease in the brain, lungs, liver, spleen, kidneys, bone marrow, heart and/or skeletal muscle. Taken  
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Figure 4. TRAP1 expression in non-neoplastic murine tissues.  
In wild-type mice, TRAP1 was diffusely expressed in the heart (A), brown fat (B, C and D, top panel), peri-venular 
hepatocytes (E), splenic red pulp histiocytes (F) and renal tubular cells (H). Consistent negativity was instead observed 
in skeletal muscles (B, lower panel), peripheral nerves (C, mid to lower panel), pneumocytes and blood vessels (D, top 
to lower panel), splenic white pulp (F), colonic epithelial cells and lymphoid follicles (G) and renal glomeruli (H). 
(Peroxidase stains; original magnification 10x and 20x). 
________________________________________________________________________________ 
 
together, these results suggest slightly different metabolic features and reduced biological 
aggressiveness for subcutaneous xenograft of immortalized MPNST cells. 
 
 4.2 TRAP1 in non-neoplastic and neoplastic lymphoid cells 
 Most studies addressing TRAP1-related oncogenesis have focused on solid tumor models. 
Little is instead known on TRAP1 expression in non-neoplastic and neoplastic lymphoid cells. To fill 
this gap, the hematologic tumor branch of the present study first assessed TRAP1 expression in a 
series of non-neoplastic (i.e. reactive) lymph nodes and tonsils. The obtained results prompted the 
immunohistochemical characterization of selected lymphoma entities. 
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 4.2.1 TRAP1 expression in non-neoplastic lymphoid cells 
 TRAP1 immunostaining on reactive lymph nodes and tonsils disclosed a clear-cut positivity 
in a minority (10% to 40%) of GC cells. In detail, strong cytoplasmic staining was observed in both 
GC-residing macrophages (also known as “tangible body cells”) and in subsets of DZ and LZ large 
lymphoid blasts (Figure 5A-B). Mature-looking GC centrocytes and inter-follicular lymphocytes 
were consistently TRAP1-negative.  
To elucidate the nature of the TRAP1-positive GC blasts, double immunostainings were 
performed on whole tissue sections. The joint assessment of TRAP1 and PAX5 (a pan-B cell marker) 
disclosed a B-cell origin for all TRAP1-positive GC blasts (Figure 5C). Furthermore, TRAP1/IRF4 
double immunostainings showed three populations of cells: (i) a TRAP1-positive/IRF4-positive 
population of large blasts, likely representing LZ B-cells skewed toward plasma cell differentiation; 
(ii) a TRAP1-positive/IRF4-negative blast population, possibly representing a DZ-recycling blast 
pool; and (iii) a TRAP1-negative/IRF4-positive population of small-to-medium sized differentiated 
plasma cells and plasmacytoid lymphocytes (Figure 5D). TRAP1 expression in DZ-recycling blasts 
was further confirmed by TRAP1/c-Myc double immunostaining, which indeed showed the joint 
expression of the two markers in a consistent subset of GC B-blasts (Figure 5E). Finally, 
immunohistochemical analysis disclosed HIF1a expression in a sub-set of GC B-cells consistent with 
the TRAP1-positive population. These overall results highlight TRAP1 expression in specific subsets 
of GC B-cells and suggest a possible role of the TRAP1/HIF1a axis in GC-based immune responses. 
 
4.2.2 TRAP1 expression in GC-derived lymphoproliferative disorders 
The results on non-neoplastic GC B-cells led to assess TRAP1 expression in the putative 
neoplastic counterparts of such elements (i.e. GC-derived B-cell non-Hodgkin and Hodgkin 
lymphomas). This analysis was conducted at a both mRNA and protein expression level. 
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 Figure 5. TRAP1 expression in non-neoplastic and neoplastic lymphoid cells. 
A-E. In reactive lymphoid tissues, TRAP1 expression was observed in scattered GC blasts and in 
histiocytes; perifollicular lymphoid cells were TRAP1-negative (A-B). Double immunostaining for 
TRAP1 (red) and PAX5 (brown) (C) disclosed the B-cell nature of GC blasts. In particular, double 
immunostaining for TRAP1 (red) and IRF4 (brown) (D) and for TRAP1 (red) and c-Myc (brown) (E) 
highlighted TRAP1 expression in both re-cycling GC blasts (panel D, black arrowhead; panel E, white 
arrowheads) and plasma cell differentiating blasts (panel D, white arrowhead; panel E, black 
arrowhead). G-I. TRAP1 was diffusely expressed in the neoplastic cells of BL (F), DLBCL (G), cHL 
(bi-nucleated Reed-Sternberg and mononuclear Hodgkin cells) (H) and NLPHL (LP cells) (I). Non-
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neoplastic by-stander cells disclosed variable degrees of TRAP1 positivity (Immunoperoxidase and 
phosphatase stains; original magnification, 5x, 20x and 40x). 
 
 
Figure 6. In silico gene expression profiles of TRAP1 mRNA in GC-derived B-cell lymphomas. 
In silico gene expression profiles from the Oncomine database disclosed significantly higher TRAP1 
mRNA expression levels in Burkitt lymphoma (BL), diffuse large B-cell lymphoma (DLBCL) and 
Hodgkin lymphomas (HL) compared to non-neoplastic control B-cells. The data shown in these figure 
refers to ref.102 (single asterisk, p<0.0001; double asterisk, p<0.05). 
_________________________________________________________________________ 
 
TRAP1 mRNA expression was assessed by in silico gene expression analysis, through the Oncomine 
database (106). These search highlighted TRAP1 up-regulation in BL, DLBCL and HL compared to 
control (i.e. non-neoplastic) B-cells and other lymphoma entities (p<0.05) (Figure 6). Of note, in all 
the available data sets, BL was associated with the highest TRAP1 mRNA levels. 
Moving from these in silico data, TRAP1 protein expression was investigated in 
representative primary samples of BL, DLBCL (both GCB and non-GCB type) and HL. In keeping 
with the gene expression analysis, TRAP1 was strongly and diffusely expressed in all BLs and in the 
vast majority of DLBCLs (32/33 cases [96.7%]), although with different intensity (from >80% to 
40% of neoplastic cells) (Figure 5F-G). In DLBCL, the intensity and distribution of TRAP1 did not 
clearly correlate with a CGB or non-GCB phenotype. The protein was also strongly expressed in the 
neoplastic elements of both cHL (HRS cells) and NLPHL (LP cells) (Figure 5H-I). 
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5. DISCUSSION 
 
The study of tumor cell biology largely relies on in vivo and in vitro models, recapitulating 
the basic molecular features of human neoplasms. This approach is instrumental to understand cancer 
biology, as it allows the characterization and genetic manipulation of homogeneous cell populations, 
while working in standardized experimental conditions. These advantages may nonetheless limit the 
clinical application of basic research studies, as human tumors are often much more complex than 
their in vitro/in vivo counterparts (109, 110).  
Moving from these premises, the present project aimed to integrate the results of in vitro and 
in vivo studies on TRAP1-related oncogenesis (46, 64) with a thorough histological characterization 
of primary human samples. This led to compare the morphological and immunohistochemical 
features of primary human neoplasms and animal tumor models, also disclosing novel fields for the 
study of TRAP1-related oncogenic cascades.  
The histological characterization of NF1-related peripheral nerve sheath tumors provided 
unprecedented information on the up-regulation of TRAP1 and its down-stream targets. In particular, 
it disclosed a progressive increase of TRAP1 expression from non-neoplastic tissues (i.e. peripheral 
nerve trunks) to PNs and MPNSTs. This finding is in line with what observed in other tumor models 
(e.g. TRAP1-related hepatocellular carcinogenesis) (61) and its consistency across animal species 
supports the oncogenic relevance of TRAP1-related metabolic reprogramming. In particular, 
immunohistochemical analysis confirmed the biological validity of prior in vitro oncogenic studies 
on Nf1-silenced stromal cells, which disclosed a pseudo-neoplastic phenotype as a consequence of 
MAPK pathway up-regulation, pERK1/2-mediated TRAP1 phosphorylation and HIF1a stabilization 
(46).  
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Quite notably, histological studies disclosed a diversified up-regulation of HIF1 target genes. 
Both human samples and animal tumor models indeed demonstrated a higher expression of PKM2 as 
compared to other proteins involved in glucose metabolism (e.g. GLUT1 and HK2) (Figure 3A). The 
reasons for such a difference are largely unknown, but the biochemical properties of PKM2 may 
provide a biological rationale for its more consistent up-regulation.  
PKM2 is a tumor-specific variant of the last enzyme of the glycolytic pathway (pyruvate 
kinase [PK]). Compared to other PK variants, it has a reduced catalytic activity and is inhibited by 
growth factor-dependent signaling pathways (111, 112). As such, PKM2-expressing tumors are 
characterized by a reduced funneling of the glycolytic flow towards the TCA cycle and by the 
accumulation of metabolic intermediates that can be diverted into anabolic pathways (22). The unique 
features of PMK2 and the metabolic consequences of its over-expression are thus likely sufficient to 
provide tumor cells with an anabolic phenotype and may largely vicariate the limited up-regulation 
of glucose transporters (e.g. GLUT1) and/or other glycolytic enzymes (e.g. HK2). Furthermore, 
PKM2 contributes to the metabolic reprogramming of tumor cells by directly binding and co-
activating HIF1 (113). All of these features possibly justify the prominent up-regulation of this 
enzyme, as compared with other glucose metabolism-related genes. 
Morphometric and immunohistochemical studies on engineered mouse models also 
contributed to highlight the importance of TRAP1 in PN and MPNST oncogenesis. In particular, 
morphometric analyses disclosed a reduced size for shTRAP1 PNs compared to wild-type tumors 
(Figure 3B). This limited growing potential was not observed in shTRAP1 MPNSTs, suggesting the 
existence of TRAP1-independent oncogenic pathways that propel malignant tumor cell proliferation. 
Of note, TRAP1 silencing was associated with a reduced expression of HIF1a, its downstream targets 
(e.g. GLUT1, HK2 and PKM2) and GLUL. Taken together, these results may suggest a role for 
TRAP1 in glucose and glutamine metabolic reprogramming and in the acquisition of a fully 
neoplastic phenotype . Further in vitro and in vivo studies are need to confirm these histological data. 
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Immunohistochemical analysis was also applied to xenograft models of NF1-related MPNSTs 
(i.e. PDTXs and murine xenograft of the immortalized cysMPNST cell line). While the 
morphological and immunohistochemical features of PDTXs overlapped those of primary human 
samples and engineered mice, cisMPNST xenografts partially diverge from them. This inconsistency 
is likely related to the aberrant phenotypic and molecular features, which typically characterize 
immortalized cell lines as compared to their human counterpart (110). This drawback should limit 
the use of such model in future metabolic studies. Nonetheless, the subcutaneous injection of 
immortalized cisMPNST cells proved instrumental to assess the behavior and limited metastatic 
potential of heterotopic xenografts of NF1-related peripheral nerve sheath tumors. 
With respect to the hematological branch of this study, histological analysis contributed to 
expand the spectrum of TRAP1-expressing human neoplasms. Prior studies on TRAP1-related 
oncogenic cascades indeed focused on solid tumor models (46, 61, 114-117), while little (if any) 
information was available on TRAP1 expression in lymphoproliferative disorders. Moving from a 
thorough phenotypic characterization of reactive lymphoid tissues, this study highlighted TRAP1 
expression in non-neoplastic re-cycling and differentiating GC blasts, in GC-derived high-grade B-
cell lymphomas (i.e. BL and DLBCL) and in the neoplastic blasts (i.e. HRS and LP cells) of HL.  
From a pathogenic viewpoint, TRAP1 expression in such lymphomas may stem: (i) from the 
protein constitutive positivity in their non-neoplastic counterparts; and/or (ii) from disease-specific 
molecular derangements. In fact, some evidence suggests that c-Myc directly binds TRAP1 promoter 
and induces its over-expression (118). Of note, virtually all BLs and HLs and a consistent subset of 
DLBCLs are characterized by moderate to high c-Myc expression levels, as a result of recurrent 
chromosomal translocations (BL and some DLBCLs) or disease-specific gene expression profiles 
(HL and subsets of DLBCL) (81, 119). In such tumors, it is thus possible that TRAP1 positivity 
directly stems from the constitutive expression of c-Myc. Taken together, these data suggest a 
complex molecular scenario, whereby TRAP1 over-expression in GC-derived B-cell lymphomas may 
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depend on the tumor origin (i.e. TRAP1-expressing GC blasts) as well as on disease-specific genetic 
derangements. This is further sustained by the variability of TRAP1-positive cells among DLBCLs. 
DLBCLs are very heterogeneous neoplasms, characterized by distinct molecular and 
metabolic features. Gene expression studies have indeed highlighted the existence of metabolically 
diverse sub-groups, relying on either oxidative phosphorylation (i.e OxPhos signature) or aerobic 
glycolysis (i.e. BCR signature) for their energetic needs (91). The OxPhos signature is characterized 
by the hyper-expression of respiratory chain components (e.g. complex I and complex II), ATP 
synthase and pyruvate dehydrogenase subunits and several TCA cycle enzymes. By contrast, the BCR 
signature is associated with reduced mitochondrial respiration and fatty acid oxidation and with 
increased glycolytic flux (120). These data may explain the variability of TRAP1 expression among 
DLBCLs. In fact, those cases with enhanced glycolytic features (i.e. BCR signature) may be 
associated with TRAP1 over-expression. By contrast, the OxPhos signature putatively relies on 
TRAP1-unrelated metabolic programs and may include cases with reduced TRAP1 expression. 
Further genetic and molecular studies are needed to test this hypothesis and to investigate any possible 
correlation between TRAP1 expression and the metabolic features of DLBCL. 
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6. CONCLUSIONS 
 
This study highlights the contribution of histology to the understanding of tumor metabolism. 
Morphological and immunohistochemical analyses integrate the results of in vitro and in vivo studies 
and identify novel fields for tumor metabolic investigations.  
In particular, histology confirms the relevance of TRAP1 activation in NF1-related peripheral 
nerve sheath tumors and discloses a tight correspondence between the pathological (i.e. 
morphological) features of primary human samples and animal tumor models. Immunohistochemical 
characterization of reactive lymphoid tissues and primary lymphoma samples also identifies recurrent 
TRAP1 expression profiles, possibly subtending tumor-related metabolic networks. 
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